<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278434</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000460044</org_study_id>
    <secondary_id>UCSF-03421</secondary_id>
    <secondary_id>UCSF-H7810-25693-01</secondary_id>
    <secondary_id>UCSF-H7810-25693-02A</secondary_id>
    <nct_id>NCT00278434</nct_id>
  </id_info>
  <brief_title>Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3</brief_title>
  <official_title>An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep tumors from forming, growing,&#xD;
      or coming back. Zoledronate may prevent the growth of cervical cancer by blocking blood flow&#xD;
      to cervical intraepithelial neoplasia cells. The use of zoledronate may keep cancer from&#xD;
      forming.&#xD;
&#xD;
      PURPOSE: This randomized is studying how well zoledronate works in treating patients with&#xD;
      cervical intraepithelial neoplasia 2/3 or 3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess clinical response, in terms of lesion size and histological grade, of oledronate&#xD;
           in patients with cervical intraepithelial neoplasia 2/3 or 3.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, double-blind, pilot study. Patients are&#xD;
      stratified according to degree of cervical intraepithelial neoplasia (CIN) (CIN2/3 vs CIN3).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Zoledronate: 100 cc of saline with 4 mg of Zoledronate intravenous (IV), over 20&#xD;
           minutes, for 3 doses one week apart&#xD;
&#xD;
        -  Placebo: 100 cc of saline (IV), over 20 minutes, for 3 doses one week apart&#xD;
&#xD;
      In both arms, treatment repeats every 21 days for up to 3 courses. In week 8, patients&#xD;
      undergo surgical resection comprising loop excision or cone biopsy.&#xD;
&#xD;
      After completion of study treatment, patients are followed at week 10 by telephone.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual was insufficient to meet study endpoints&#xD;
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of Zoledronic Acid (ZA) on clinical response</measure>
    <time_frame>10 weeks from start of treatment</time_frame>
    <description>The primary objective is to determine whether Zoledronic Acid (ZA), when given to women with CIN 2/3 or 3 for two months prior to surgical excision, has a measurable impact on clinical response (lesion size and histological grade).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Zoledronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart&#xD;
Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.&#xD;
After completion of study treatment, patients are followed at week 10 by telephone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 cc of saline IV, over 20 minutes, for 3 doses one week apart&#xD;
Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.&#xD;
After completion of study treatment, patients are followed at week 10 by telephone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronate</intervention_name>
    <arm_group_label>Zoledronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Saline)</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy confirmed cervical intraepithelial neoplasia (CIN) 2/3 or 3&#xD;
&#xD;
               -  Planning loop excision or cone biopsy&#xD;
&#xD;
               -  Diagnosis within 2 months prior to study entry&#xD;
&#xD;
               -  Standard histological grading according to Richart&#xD;
&#xD;
          -  Visible lesion by colposcopy&#xD;
&#xD;
               -  No unsatisfactory colposcopy or lesions extending into the endocervical canal&#xD;
                  that cannot be visualized entirely by colposcopy&#xD;
&#xD;
          -  No suspicion of invasive cervical cancer by cytology, histology or colposcopy&#xD;
&#xD;
          -  No cytologic evidence of glandular atypia or dysplasia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Screening laboratory values within normal range (e.g., complete blood count, liver&#xD;
             function tests, renal panel, and electrolytes)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to read and speak English or Spanish&#xD;
&#xD;
          -  No known hypersensitivity to bisphosphonates&#xD;
&#xD;
          -  Not immunocompromised&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No aspirin-sensitive asthma due to association of bisphosphonates with&#xD;
             bronchoconstriction&#xD;
&#xD;
          -  No unexplained abnormal vaginal bleeding&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent loop diuretics, aminoglycosides, other nephrotoxic drugs,&#xD;
             immunosuppressive drugs, or other investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Smith-McCune, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>cervical intraepithelial neoplasia grade 2</keyword>
  <keyword>cervical intraepithelial neoplasia grade 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

